Perrigo Company plc (NYSE:PRGO) Shares Purchased by Bahl & Gaynor Inc.

Bahl & Gaynor Inc. lifted its position in Perrigo Company plc (NYSE:PRGO) by 1.4% during the fourth quarter, HoldingsChannel.com reports. The fund owned 839,558 shares of the company’s stock after acquiring an additional 11,913 shares during the period. Bahl & Gaynor Inc.’s holdings in Perrigo were worth $27,017,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. London Co. of Virginia boosted its stake in Perrigo by 1.1% during the third quarter. London Co. of Virginia now owns 2,818,468 shares of the company’s stock worth $90,050,000 after buying an additional 30,239 shares during the last quarter. Cooper Creek Partners Management LLC boosted its stake in Perrigo by 1,080.0% during the third quarter. Cooper Creek Partners Management LLC now owns 1,872,508 shares of the company’s stock worth $59,827,000 after buying an additional 1,713,827 shares during the last quarter. Northern Trust Corp boosted its stake in Perrigo by 0.3% during the third quarter. Northern Trust Corp now owns 1,582,731 shares of the company’s stock worth $50,568,000 after buying an additional 4,373 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Perrigo by 5.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,379,041 shares of the company’s stock worth $44,060,000 after buying an additional 65,123 shares during the last quarter. Finally, Heartland Advisors Inc. boosted its stake in Perrigo by 17.2% during the third quarter. Heartland Advisors Inc. now owns 1,124,596 shares of the company’s stock worth $35,931,000 after buying an additional 164,849 shares during the last quarter. 95.91% of the stock is owned by institutional investors and hedge funds.

Perrigo Trading Up 2.1 %

NYSE:PRGO traded up $0.67 on Friday, reaching $31.94. The company’s stock had a trading volume of 945,679 shares, compared to its average volume of 1,812,863. Perrigo Company plc has a 12-month low of $25.77 and a 12-month high of $40.28. The company has a quick ratio of 1.07, a current ratio of 1.79 and a debt-to-equity ratio of 0.76. The firm has a market cap of $4.33 billion, a price-to-earnings ratio of -319.40 and a beta of 0.64. The stock has a 50 day moving average price of $30.52 and a 200 day moving average price of $30.80.

Perrigo (NYSE:PRGO) last posted its earnings results on Tuesday, February 27th. The company reported $0.86 EPS for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. Perrigo had a positive return on equity of 7.34% and a negative net margin of 0.27%. The company had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.17 billion. During the same quarter in the previous year, the business earned $0.75 earnings per share. The company’s revenue for the quarter was up .1% on a year-over-year basis. On average, equities analysts anticipate that Perrigo Company plc will post 2.55 EPS for the current fiscal year.

Perrigo Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 26th. Investors of record on Friday, March 8th were issued a $0.276 dividend. This represents a $1.10 annualized dividend and a dividend yield of 3.46%. The ex-dividend date of this dividend was Thursday, March 7th. This is an increase from Perrigo’s previous quarterly dividend of $0.27. Perrigo’s payout ratio is currently -1,100.00%.

Insider Activity at Perrigo

In other news, CEO Patrick Lockwood-Taylor acquired 9,500 shares of the business’s stock in a transaction that occurred on Thursday, February 29th. The shares were purchased at an average price of $26.54 per share, for a total transaction of $252,130.00. Following the acquisition, the chief executive officer now owns 20,500 shares of the company’s stock, valued at $544,070. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In related news, CEO Patrick Lockwood-Taylor purchased 9,500 shares of the business’s stock in a transaction on Thursday, February 29th. The shares were bought at an average price of $26.54 per share, for a total transaction of $252,130.00. Following the acquisition, the chief executive officer now directly owns 20,500 shares in the company, valued at $544,070. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Alison Ives purchased 2,490 shares of the business’s stock in a transaction on Tuesday, March 5th. The shares were bought at an average price of $27.26 per share, for a total transaction of $67,877.40. Following the acquisition, the executive vice president now owns 16,122 shares in the company, valued at $439,485.72. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 17,990 shares of company stock worth $475,227. 0.70% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on PRGO. JPMorgan Chase & Co. lowered their price objective on Perrigo from $48.00 to $41.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 28th. Piper Sandler boosted their price objective on Perrigo from $35.00 to $39.00 and gave the stock an “overweight” rating in a research note on Monday, April 8th. Canaccord Genuity Group reissued a “buy” rating and set a $42.00 price objective on shares of Perrigo in a research note on Friday, April 12th. Finally, StockNews.com upgraded Perrigo from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd.

Perrigo Profile

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.